Vivimed Labs Limited Receives Notice from CBI Regarding SBI Complaint
Vivimed Labs Limited received a notice from the CBI concerning a complaint by State Bank of India regarding financial irregularities. This follows Rare ARC's acquisition of the company's financial assets from SBI.
A notice from the CBI and allegations of financial irregularities can significantly impact the company's reputation, operations, and stock value.
The company has received a notice from the CBI related to a complaint about financial irregularities, which indicates potential legal and financial trouble.
Vivimed Labs Limited has disclosed receiving a notice dated January 27, 2026, from the Central Bureau of Investigation (CBI), Banking Securities Fraud Branch, Bengaluru, via an email dated January 29, 2026. This notice is in relation to a complaint filed by the State Bank of India (SBI), IFB Branch, Hyderabad, concerning alleged financial irregularities.
Previously, on October 25, 2025, the company had intimated that Rare Asset Reconstruction Ltd. (Rare ARC) acquired its financial assets, along with all associated security interests, rights, title, interest, and benefits, through Assignment Agreements (AA) with State Bank of India. Rare ARC is now entitled to recover the total dues payable to SBI, including interest at contractual rates, further interest, and other charges until the date of realization from Vivimed Labs Limited as the borrower and any guarantors.
This disclosure is made for the information and appropriate dissemination to the stock exchanges.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under fraud/defaults disclosure. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.